D
ual antiplatelet therapy remains the cornerstone of the medical management of patients with acute coronary syndrome (ACS). In ACS patients receiving a coronary stent, the combination of aspirin and a P2Y 12 inhibitor reduces rates of stent thrombosis and major adverse cardiovascular events. Given the well-known limitations of clopidogrel with variable antiplatelet effects and delayed onset of action, newer P2Y 12 inhibitors have been developed (Table) . In randomized controlled clinical trials, prasugrel and ticagrelor reduce rates of major adverse cardiovascular events compared with clopidogrel, although both agents are associated with increased bleeding complications. 1, 2 Despite the clear benefits of these agents in randomized controlled clinical trials and meta-analyses, contemporary use in clinical practice appears to be low. 3 Factors associated with the decision to select a particular P2Y 12 inhibitor for the management of patients with ACS are complex, multifactorial, and poorly described. In this issue of the Journal, Vora et al studied 11 969 patients enrolled in the Treatment With ADP Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome (TRANSLATE-ACS) study to explore how antiplatelet therapy is selected for patients with acute myocardial infarction (MI) undergoing percutaneous coronary intervention (PCI). 4 TRANSLATE-ACS is a well-described contemporary registry of ACS patients treated at >200 hospitals throughout the United States. 5 Prasugrel was used in 26% of patients, and those patients tended to be younger, less likely female, and more likely to have private insurance than clopidogrel-treated patients.
Factors associated with prasugrel use were cardiogenic shock, drug-eluting stent implantation, and presentation with an ST-segment elevation MI. To explore the relative importance of ischemia or mortality and bleeding when selecting a P2Y 12 inhibitor, patients were classified as having high or low Acute Coronary Treatment and Intervention Outcomes (ACTION) mortality and bleeding risk scores. The highest use of prasugrel was seen in patients with both a low bleeding score and a low mortality score. These findings suggest that physicians may perceive bleeding risk as a more important factor compared with ischemia or mortality risk when selecting a P2Y 12 inhibitor. The current study and others clearly show the difficulty that physicians face when weighing the benefits and risks of antiplatelet therapy. The benefits of enhanced antiplatelet therapy with a reduction in ischemic risk occur at the cost of increased bleeding events. The results of the current analysis apply only to patients with acute MI undergoing PCI. The selection of a specific P2Y 12 inhibitor in ACS patients receiving medical therapy alone without PCI is likely to be even more complex. The authors clearly outlined the limitations of the current analysis including the inability to account for unmeasured cofounders in this registry cohort, the lack of provider-reported rationales for P2Y 12 inhibitor selection, and the limited ability of the applied risk models to accurately assess mortality and bleeding risk. In addition, several other factors may be difficult and/or impossible to study and may also affect the selection of a particular P2Y 12 inhibitor. Participation in clinical trials evaluating new drugs often enhances a physician's ability to adopt newer agents into routine clinical practice following US Food and Drug Administration (FDA) approval. Although all hospitals participating in the TRANS-LATE-ACS study were approved for inpatient prasugrel use, significant barriers often exist for long-term outpatient approval and receipt of prasugrel; physician knowledge of this difficulty could potentially discourage initial selection of this agent. Although a small number of patients initiated on >1 P2Y 12 inhibitor were excluded, and no information was provided for patients who switched between different P2Y 12 The opinions expressed in this article are not necessarily those of the editors or of the American Heart Association. inhibitors, which may happen frequently in clinical practice. 6, 7 Although these results are contemporary, patients were enrolled until October 2012; ticagrelor received FDA approval in 2011 and thus was not widely adopted during the study period. An intravenous P2Y 12 inhibitor (cangrelor) has also recently received FDA approval. The role of these 2 additional agents in contemporary practice remains unclear. Several other investigators have explored similar issues regarding the contemporary selection of antiplatelet therapy. 8 Perhaps the most important finding of this study was that prasugrel was used in 34% of ACS patients with a documented contraindication (history of stroke or transient ischemic accident, age >75 years, and body weight <60 kg). The selection of newer P2Y 12 inhibitors may be even more complex in European countries. 10, 11 Indirectly related to the current discussion for coronary indications is that the use of P2Y 12 inhibitors in patients undergoing endovascular intervention appears to be even more variable, with less data from contemporary clinical practice. 12 A recent publication using data from the Centers for Medicare and Medicaid Services found that a P2Y 12 inhibitor was used in only 81% of patients undergoing an endovascular procedure. 13 Physician specialty and the clinical setting in which the procedure was performed (inpatient, outpatient, or office) were strongly associated with P2Y 12 inhibitor use. In this particular study, all current P2Y 12 inhibitors were included as a single category, such that relative use of a particular agent could not be evaluated. Additional studies should continue to explore reasons for selection of specific P2Y 12 inhibitors in both coronary and endovascular intervention. Targeting patients at the highest risk for ischemic events, with an acceptable bleeding risk, should allow the most effective and safest use of the newer P2Y 12 inhibitors. 
